Harrow announced the execution of a 5-year strategic supply and development (SSD) agreement for Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is approved by the US Food and Drug Administration (FDA) for visualization during vitrectomy and the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. The SSD agreement is with the current contract manufacturing organization producing Triesence, ensuring continuity in quality and leveraging more than 15 years of experience with the Triesence manufacturing process, Harrow said in a press release. 

In addition, Harrow announced that it has begun developing a next-generation version of Triesence and plans to submit a new drug application to the FDA before the end of 2027.

“When we acquired Triesence, our first objective was to stabilize its supply and keep it off the FDA’s Drug Shortage List, where it had been for more than 5 years," said Mark L. Baum, chairman and chief executive officer of Harrow, in the press release. "By finalizing this strategic supply and development agreement, we’re ensuring the continued production of Triesence under a trusted partnership with a world-class ophthalmic pharmaceutical manufacturer. At the same time, we’re developing an enhanced version of Triesence, designed to deliver added value for physicians and their patients. These 2 initiatives—securing reliable supply and advancing a next-generation product—underscore our commitment to bolstering the Triesence brand and meeting the evolving needs of the ophthalmic community.”

According to Harrow, Triesence (J-Code 3300) is available to health care providers directly through major pharmaceutical wholesale distributors, including Cencora, Cardinal Health, and McKesson.